Reveal Biosciences announced a partnership agreement with Affymetrix that will enable Reveal to offer new RNA biomarker validation services. Reveal will use Affymetrix ViewRNA ISH products combined with their proprietary ImageDx software to provide RNA in situ hybridization (ISH) staining, imaging and quantification services.
“We are thrilled to partner with Affymetrix to provide high-quality services using ViewRNA products. Our scientific expertise, combined with high-resolution imaging and our proprietary image analysis software, ImageDx™, form a powerful platform for the localization and quantification of mRNA in tissue samples,” said Dr. Claire Weston, CEO and founder of Reveal Biosciences. “This highly sensitive technology is changing the face of mRNA biomarker screening and analysis for translational research and diagnostics.”
Reveal Biosciences is a leading provider of advanced tissue technology services and tissue-based research. The company’s portfolio includes in situ hybridization (ISH), immunohistochemistry (IHC), immunofluorescence (IF), and histology. Reveal enhances these services with proprietary technologies for NGPx™ Next Generation Pathology, multiplexing, whole-slide imaging, and ImageDx™ image analysis software as a service. For more information about Reveal Biosciences, please visit:http://www.revealbio.com.